ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

 

ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy
Avatar

Molecular Milestones Using the BCR-ABL1 qPCR Level and Doubling Time After Imatinib Discontinuation to Predict Successful Treatment-free Remission: Treatment-free Remission Accomplished by Dasatinib (TRAD) Trial

By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Dennis Kim
By ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy FEATURING Dennis Kim
15 views
November 23, 2018
Comments 0
Login to view comments. Click here to Login
Scientific Session 7: Treatment-free Remission
12:56

Molecular Milestones Using the BCR-ABL1 qPCR Level and Doubling Time…

ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

D. Kim

15 views
18:28

What Prevents the Disease from Relapsing after TKI Discontinuation

ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

S. Mustjoki

15 views
11:10

Treatment-free Remission in Patients with Chronic Phase Chronic Myel…

ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy

S. Saussele

30 views